The biotech firm Moderna’s stock price has risen sharply since the release of preliminary trial results for its experimental personalized cancer vaccine. This represents the first true test of the innovative approach which, if successful, could represent a turning point for both the company itself and for the field as a whole.
Moderna is developing its vaccine in collaboration with the multinational pharmaceutical firm Merck & Co., Inc. (Merck). It is being tested in conjunction with Merck’s widely used cancer medication Keytruda. What sets this vaccine apart is that it utilizes Moderna’s mRNA technology to develop a tailored vaccine for each patient based upon genetic mutations in their individual tumors.
The Phase III clinical trial included over 1100 patients with stage IIIc melanoma, all of whom underwent surgical removal of their tumors prior to participating in the study. In the trial, the combination of the vaccine and Keytruda achieved its primary objective i.e. delaying both recurrence and metastasis of cancer.
In addition to demonstrating efficacy, the two firms reported that there were no previously unknown safety issues related to either the vaccine or Keytruda during the course of the trial. Data will be shared in greater detail at a forthcoming scientific conference and ultimately submitted to regulatory agencies.
Moderna’s stock increased in excess of 90 percent in pre-market trading. Additionally, Merck’s stock rose in response to news about the vaccine’s success.
Investors reacted positively to these developments because they indicate that Moderna may be able to extend its platform beyond the COVID-19 vaccine business into cancer treatments. The two companies claim that the Phase III trial represents the first successful demonstration of mRNA-based cancer therapies.
Cancer treatments typically differ from conventional vaccinations in that they are designed to enable a patient’s immune system to attack existing cancer cells rather than preventing future infections.
In order to generate such a treatment, researchers must determine the unique mutations present within a given patient’s tumor. That information is then used to create an individualized mRNA-based vaccine that trains the immune system to recognize features of the patient’s particular type of cancer cell.
Therefore, unlike many vaccines that provide protection against multiple pathogens, mRNA-based cancer vaccines are intended to be customized to address each individual patient’s needs.
Early studies have shown similar positive results; five years post-treatment data from an early-phase trial showed a statistically significant reduction in melanoma recurrence rates when administered with Keytruda relative to Keytruda alone.
However, the intismeran autogene vaccine is currently classified as an experimental treatment. Although Moderna and Merck are hopeful regarding the possibility of obtaining regulatory approval for intismeran autogene once the current Phase III results have been finalized, the product has not received formal FDA approval.
Following review by regulatory bodies, Moderna and Merck plan to submit complete details of the Phase III study. Thus, while completion of the study marks a major milestone in development of the treatment, it does not mean that physicians can immediately begin prescribing intismeran to their patients on a routine basis.
2026-08-19 19:02:00
